Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR0602 With Nivolumab in NSCLC and mCRPC, and STAR0602 Alone in Thymic Carcinoma
NCT07902921Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of invikafusp alfa in non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and thymic carcinoma (TC) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Safety of STAR0602 monotherapy and combination and Progression-Free Survival up to 5 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
invikafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT07902921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902921.